The HAX1 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population engineered to disrupt the human HAX1 gene. This product provides a loss-of-function model system in a near-haploid human cell background, enabling functional studies of HAX1 without the complexity of diploid gene compensation. The polyclonal format offers a population-based knockout, suitable for pooled phenotypic assays and screening applications where clonal heterogeneity can be beneficial to capture a range of functional outcomes.
The HAP1 host cell line is derived from the KBM-7 chronic myeloid leukemia (CML) cell line, which was isolated from a patient in blast crisis. HAP1 cells retain a near-haploid karyotype except for a disomic chromosome 8, making them an ideal substrate for genetic screens because disruption of a single allele is typically sufficient to produce a functional knockout. Their CML origin and intact apoptotic machinery render them particularly relevant for studying mechanisms of leukemogenesis and drug resistance.
HAX1 (HS1-associated protein X-1) is a ubiquitously expressed anti-apoptotic protein that localizes to mitochondria, the endoplasmic reticulum, and the cell cortex. The mechanistic summary provided with this product indicates that HAX1 exerts its anti-apoptotic function by directly binding to BCL2 and BCL-XL, stabilizing mitochondrial membrane potential and thereby inhibiting caspase-3 activation. Upstream, HAX1 expression is promoted by the IL-3/GATA1 signaling axis and is subject to caspase-3-mediated cleavage during apoptosis. In addition to apoptosis, HAX1 regulates cell migration and endocytosis through interactions with cortactin, PKD2, and GNA13/RhoA. These molecular connections place HAX1 at the intersection of apoptotic regulation, integrin signaling, and GPCR-mediated pathways.
Knockout of HAX1 in the HAP1 background creates a powerful model to dissect the roles of HAX1 in leukemogenesis and mitochondrial apoptosis. Given the well-characterized apoptosis machinery in HAP1 cells, loss of HAX1 is expected to sensitize these cells to intrinsic apoptotic stimuli, making this polyclonal knockout population useful for comparing dose-response profiles of chemotherapeutic agents that target the mitochondrial pathway. Moreover, the near-haploid genetics facilitate straightforward interpretation of results in migration and endocytosis assays, as clonal variation due to allelic differences is minimized.
This HAX1 knockout model supports a broad range of experimental applications. Researchers can employ Annexin V/propidium iodide staining and JC-1 mitochondrial membrane potential assays to quantify apoptosis, as well as caspase-3 activity assays to assess downstream effector activation. Transwell migration assays can be used to evaluate the impact of HAX1 loss on directed cell motility. Co-immunoprecipitation studies enable mapping of protein?protein interactions involving BCL2, BCL-XL, cortactin, and other binding partners. Additionally, this model is valuable for congenital neutropenia research and for screening small-molecule modulators of the HAX1 pathway. For further technical details or assistance, please contact Ascent Research.
